Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3)
Funds the clinical validation of a cancer biomarker assay whose analytical performance has already been proven.
A cancer biomarker only becomes useful when someone shows the assay behaves the same way in real patient specimens, in more than one laboratory, on more than one occasion. The National Cancer Institute funds that step here, and only that step.
The markers in scope are molecular, cellular or imaging, and the uses named are detection, diagnosis, prognosis, monitoring, prediction of response or resi…
Clinical validation, over up to three years, of analytically validated molecular, cellular or imaging assays for cancer detection, diagnosis, prognosis, monitoring, response prediction, prevention and control, including pharmacodynamic and toxicity markers, and cross-laboratory harmonisation, using specimens from retrospective or prospective studies.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up